Evaxion Biotech A/S announced on January 15, 2025, the completion of dosing for all 16 patients in its Phase 2 trial with EVX-01. EVX-01 is a personalized cancer vaccine designed with Evaxion’s AI-Immunology platform, developed as a treatment for advanced melanoma.
This milestone signifies a crucial step forward in the clinical development of the company's lead asset. The trial remains on track for its completion and the highly anticipated data readout in the second half of 2025.
The completion of dosing allows the company to focus on collecting and analyzing the long-term efficacy and safety data from the trial, which will be vital for future development and potential partnership discussions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.